Akorn Inc. said the U.S. Food and Drug Administration approved its abbreviated new drug application for bimatoprost ophthalmic solution to treat a hair condition relating to eyelashes.

The FDA approved the company's bimatoprost ophthalmic solution to treat hypotrichosis — a condition of abnormal hair patterns, predominantly loss or reduction — of the eyelashes by increasing their growth including length, thickness and darkness.

The Lake Forest, Ill.-based generic-drug maker's stock price rose 6.19% to $6.86 in premarket trading on Oct. 10, but after markets opened, it fell 2.01% to $6.34 as of 10:26 a.m. ET.

According to IQVIA, sales of the solution totaled about $63.5 million for the year ended August 2018.